Abstract 590P
Background
KRAS mutations are the most common molecular alteration in NSCLC, with the KRAS G12C variant reported in 12-13% of Western patients. We sought to determine the prevalence and characteristics of Australian pts with advanced NSCLC harbouring the KRAS G12C mutation.
Methods
We performed a multi-centre, retrospective review of pts diagnosed with advanced NSCLC in 2018 - 2019 for whom a KRAS result was available. Comprehensive clinicopathological and outcome data was collected and analysed for all KRAS G12C patients, and subsets of pts with non-G12C mutations (KRAS other) and KRAS wild type (KRAS WT).
Results
1085 pts from 17 sites were included, of whom 189 (17.4%) were KRAS G12C. Comprehensive data was collected on 163 KRAS G12C, 116 KRAS other and 104 KRAS WT pts. Baseline characteristics are summarised in the table. The 3 cohorts were similar in terms of age, sex, ECOG and metastatic disease at diagnosis. The KRAS G12C cohort had fewer never smokers (p <0.0001) and a trend to more PDL1 ≥50% patients (p=0.10) than the KRAS WT cohort. Comparable proportions in each cohort received any systemic therapy or any immunotherapy for advanced disease, with a similar number of lines of therapy delivered. Only 3 KRAS G12C patients received targeted therapy because of limited access. Median overall survival (mOS) in the KRAS G12Ccohort was 11.9 months (mo), compared to 17.0 mo in the KRAS other cohort (p=0.34), 26.8 mo in the KRAS WTcohort (p=0.02) and 17.6 mo in the KRAS WT cohort with EGFR/ALK/ROS1 mutated patients excluded (p=0.17). Table: 590P
KRAS G12C(n=163) | KRAS other (n=116) | KRAS WT(n=104) | All patients (n=383) | |
Age at diagnosis, years (range) | 66 (42-92) | 68 (41-89) | 69 (29-88) | 67 (29-92) |
Sex, n (%) | ||||
• Male | 84 (52) | 66 (57) | 61 (59) | 211 (55) |
• Female | 79 (48) | 50 (43) | 43 (41) | 172 (45) |
ECOG, n (%) | ||||
• 0-1 | 116 (71) | 81 (70) | 77 (74) | 274 (72) |
• 2+ | 23 (14) | 17 (15) | 9 (9) | 49 (13) |
• NA | 24 (15) | 18 (16) | 18 (17) | 60 (16) |
Smoking status, n (%) | ||||
• Current / past | 153 (94) | 107 (92) | 76 (73) | 336 (88) |
• Never | 3 (2) | 7 (6) | 21 (20) | 31 (8) |
• NA | 7 (4) | 2 (2) | 7 (7) | 16 (4) |
PDL1 result, n (%) | ||||
• <1% | 24 (15) | 17 (15) | 21 (20) | 62 (16) |
• 1-49% | 45 (28) | 42 (36) | 30 (29) | 117 (31) |
• ≥50% | 59 (36) | 39 (34) | 27 (26) | 125 (33) |
• Unknown | 35 (21) | 18 (16) | 26 (25) | 79 (21) |
Metastasis at diagnosis, n (%) | 137 (84) | 97 (84) | 86 (83) | 320 (84) |
Conclusions
Our study demonstrated a prevalence of KRAS G12C mutations of 17.4% among Australian pts with advanced NSCLC. The KRAS G12C, KRAS other and KRAS WT cohorts had similar patient and treatment patterns, although smoking history was more common in pts with a KRAS mutation. In the absence of other key driver mutations, there was no significant difference in mOS between cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Walter and Eliza Hall Institute of Medical Research.
Funding
Amgen.
Disclosure
B. Markman: Financial Interests, Personal, Advisory Board: Amgen, Merck, Bristol Myers Squibb, BeiGene, AstraZeneca; Financial Interests, Institutional, Research Funding: Amgen. B. Solomon: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Merck, Bristol Myers Squibb; Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche/Genentech; Financial Interests, Personal, Advisory Board: Amgen, Roche-Genentech, Eli Lilly, Takeda, Janssen; Financial Interests, Personal, Full or part-time Employment, Employed as a consultant Medical Oncologist at Peter MacCallum Cancer Centre: Peter MacCallum Cancer Centre; Financial Interests, Personal, Member of Board of Directors: Cancer Council of Victoria, Thoracic Oncology Group of Australasia; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Institutional, Steering Committee Member, Principal Investigator and Steering committee Chair: Roche/Genentech, Pfizer; Financial Interests, Institutional, Steering Committee Member: Novartis. L.M. Nott: Financial Interests, Institutional, Research Funding: Roche, Servier; Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck, Roche, Pfizer, MSD, Servier, Ipsen, AstraZeneca, Novartis; Financial Interests, Personal, Other, Honorarium: MSD, Amgen, Roche, Bristol Myers Squibb, Celgene. R. Roberts-Thomson: Financial Interests, Personal, Advisory Board: Bristol Myer Squibbb, Merck Sharpe and Dohme, Pfizer, AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol Myer Squibbb, Merck Sharpe and Dohme, Novartis, AstraZeneca, Pierre Fabre. B. Hughes: Financial Interests, Personal, Advisory Board: MSD, BMS, Pfizer, Roche, AstraZeneca, Takeda, Sanofi, Esai, Amgen; Financial Interests, Institutional, Research Funding: Amgen. N. Pavlakis: Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, AstraZeneca, Takeda, Pfizer, Roche, Amgen, BeiGene; Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, Pfizer, Roche, Takeda, Pierre-Faber, Illumina, Bayer; Financial Interests, Institutional, Research Funding: Bayer, Pfizer, Roche. S. Parakh: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, Roche, AstraZeneca; Financial Interests, Institutional, Research Funding: Bayer, Roche. D. Brungs: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD. S.E. Bowyer: Financial Interests, Personal, Advisory Board: Lilly, Ipsen, Sanofi, MSD, Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Sanofi. L. Warburton: Financial Interests, Personal, Advisory Board: Roche, Novartis, MSD, AstraZeneca, Bristol Myers Squibb. S.J. Harris: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb. S. Ramanujam: Financial Interests, Personal, Full or part-time Employment, Until April 2023: Amgen. A. Wang: Financial Interests, Personal, Full or part-time Employment: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract